You are here: Home » Companies » Industry
Business Standard

Investors ride out big-pharma slump with small-cap drugmakers

Indian pharmaceutical stock hit by quality-related sanctions against drugmakers operating abroad

Reuters  |  Mumbai 

Investors in Indian pharmaceutical stock - hit by quality-related sanctions against drugmakers operating abroad and reduced pricing power in more profitable markets- have adopted a new mantra: patience and pickiness. Fund managers said they are becoming increasingly fastidious regarding India's $16 billion drugs sector, with a preference for shares in smaller firms such as Natco Pharma Ltd and Cadila Healthcare Ltd with less exposure to the overseas issues curbing growth at larger rivals. "I think sticking to smaller players and not having a lot of exposure to very large ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, June 19 2017. 18:04 IST
RECOMMENDED FOR YOU